Epivax Inc.
Providence, RI
- UEI
- NLAVQM513F18
- CAGE
- 473V2
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- Providence, RI YLPUE9JLKUR6
-
- SAM.gov registration date
- Physical address
- 188 Valley St #424, Providence, RI 02909, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Bordetella pertussis immunogenicity prediction | CDC Pittsburgh | $200,692 | |
| Human leukocyte antigens (HLA)binding study and in-vitro characterization of epitopes. | Food and Drug Administration | $20,561 | |
| Research peptides to human MCH alleles | Medical Command (Army) | $241,128 | |
| Website | Medical Command (Army) | $60,000 |
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Cubrc, Inc. | 75F40124C00094 | $772,835 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Epivax Inc. is a for-profit, woman-owned small business based in Rhode Island that specializes in immunoinformatics and computational biology. The company applies machine learning and predictive modeling approaches to evaluate and predict the immunogenicity of therapeutic proteins, biological impurities, and vaccine candidates.
Through prime federal contract awards, Epivax has conducted research and development related to predicting the immunogenicity of pathogens like Bordetella pertussis, with the goal of improving T cell responses in vaccines. The company has received purchase order and firm-fixed price contracts from agencies such as the Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC), and National Institutes of Health (NIH) for these types of biomedical research projects. Epivax has not utilized any set-aside designations for its prime contract work.
Epivax has received prime federal grant funding from agencies like HHS, CDC, NIH, and the Food and Drug Administration (FDA) to support a range of immunoinformatics research efforts. Notable projects include improving T cell responses in vaccines through predictive modeling and validation, assessing the immunogenicity risk of process-related protein impurities in biological drugs, and developing a predictive model for host cell protein immunogenicity to facilitate biosimilar product development. Epivax has participated in programs like the NIH's Allergy and Infectious Diseases Research, CDC's Immunization Research, and FDA Research. Funding mechanisms utilized include formula grants, project grants, and cooperative agreements. Partners on these grants have included academic institutions like Saint Louis University.
Quick answers
Is Epivax Inc. registered in SAM.gov?
Yes. Epivax Inc.'s SAM.gov registration is active through December 9, 2026.
What is Epivax Inc.'s most recent federal award?
Epivax Inc.'s most recent federal grant award is PA21259, sbir, phase i, improving t cell responses in vaccines: prediction and validation using existing databases… (R43IP001225), from Office of Financial Resources (CDC), on September 30, 2023.
On GovTribe
See Epivax Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors